Stock Research: ChemoMetec

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

ChemoMetec

CPSE:CHEMM DK0060055861
75
  • Value
    79
  • Growth
    47
  • Safety
    Safety
    7
  • Combined
    33
  • Sentiment
    100
  • 360° View
    360° View
    75
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Chemometec A/S develops, manufactures, and sells analytical instruments for quantitative analysis of cells in liquids. It operates in the pharmaceutical, food processing, and agriculture industries with business areas including Instruments, Consumables, and Other (research projects). The company is based in Denmark and has a subsidiary in the USA. In the last fiscal year, the company had 173 employees, a market cap of $1,419 million, profits of $46 million, and revenue of $59 million.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 75 (better than 75% compared with alternatives) for 2025, overall professional sentiment and financial characteristics for the stock ChemoMetec are very positive. The 360° View is based on consolidating four consolidated indicators, with half below and half above average for ChemoMetec. The consolidated Sentiment Rank has a good rank of 100, which means that professional investors are more optimistic about the stock than for 100% of alternative investment opportunities. It also rates well regarding its financing structure, with the consolidated Safety Rank at 79 or better than 79% of its peers when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the stock is expensive and expects low growth. The consolidated Value Rank is only 7, meaning that the share price of ChemoMetec is on the high side, compared with indicators such as revenues, profits, and invested capital. The company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, invested capital growth,and stock returns, with its Growth Rank at 47. ...read more

more
Index
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 2-Oct-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
7 10 10 1
Growth
47 100 24 94
Safety
Safety
79 83 96 94
Sentiment
100 88 84 27
360° View
360° View
75 98 61 74
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
96 83 79 n/a
Opinions Change
97 50 50 50
Pro Holdings
n/a 77 88 31
Market Pulse
56 75 33 7
Sentiment
100 88 84 27
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
7 10 10 1
Growth
47 100 24 94
Safety Safety
79 83 96 94
Combined
33 95 30 80
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
5 10 10 10
Price vs. Earnings (P/E)
1 1 1 1
Price vs. Book (P/B)
1 1 1 1
Dividend Yield
51 49 64 1
Value
7 10 10 1
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
1 92 1 94
Profit Growth
85 78 72 82
Capital Growth
6 91 64 76
Stock Returns
93 80 8 62
Growth
47 100 24 94
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
92 93 93 97
Refinancing
19 13 30 26
Liquidity
98 100 98 96
Safety Safety
79 83 96 94

Similar Stocks

Discover high‑ranked alternatives to ChemoMetec and broaden your portfolio horizons.

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt.

BUSE:RICHTER
Country: Hungary
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Perrigo

NYSE:PRGO
Country: Ireland
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Continental

XTRA:CON
Country: Germany
Industry: Auto Parts & Equipment
Size: X-Large
Full Stock Analysis

Polski Koncern Naftowy ORLEN Spolka Akcyjna

WSE:PKN
Country: Poland
Industry: Oil & Gas Refining
Size: X-Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.